Interindividual heterogeneity in the clinicopathological features of BRAF mutated melanoma is associated with additional genetic alterations, such as TERT promoter mutations, biallelic inactivation of CDKN2A, loss of PTEN, TP53 mutations, copy number changes, increased genomic instability, and epigenetic events and factors derived from the tumor stroma [31,32,33,34]. This evidence concerns the gene TP53 and melanoma.